CTLA4 and cancer: While the use of single checkpoint inhibitors (anti-CTLA-4 or anti-PD-1) in human cancer therapies has induced remarkable long-term protective responses, these were often limited to a minority of patients [45,46,47]; investigators were thus determined to find beneficial combinatorial treatments to improve responses.